Evidence map›Paper›PMID 34313547›Full record

ArticleGut microbes

Chronic opioid use modulates human enteric microbiota and intestinal barrier integrity.

Angélica Cruz-Lebrón, Ramona Johnson, Claire Mazahery, Zach Troyer, Samira Joussef-Piña, Miguel E Quiñones-Mateu, Christopher M Strauch, Stanley L Hazen, Alan D Levine

Open access · goldAbstract readComparative Study
In one paragraph

Article in Gut microbes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 69 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Angélica Cruz-LebrónDepartments of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, USA.ORCID 0000-0002-7419-7382
Ramona JohnsonDepartments of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, USA.ORCID 0000-0002-9093-0951
Claire MazaheryDepartment of Pathology, Case Western Reserve University, Cleveland, USA.ORCID 0000-0002-9950-5433
Zach TroyerDepartments of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, USA.ORCID 0000-0002-1821-7334
Samira Joussef-PiñaDepartment of Pathology, Case Western Reserve University, Cleveland, USA.
Miguel E Quiñones-MateuDepartment of Microbiology and Immunology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.ORCID 0000-0001-9170-5601
Christopher M StrauchDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland, USA.
Stanley L HazenDepartment of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland, USA.ORCID 0000-0001-7124-6639
Alan D LevineDepartments of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, USA.ORCID 0000-0002-5706-0667
Case Western Reserve University · USCerner (United States) · USUniversity of Otago · NZ

Funding

WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Alan David Levine · 1994 to 2026
$50.0M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
Project 3: Microbiota generated aryl sulfates and secondary bile acids in cardiometabolic diseaseP01HL147823 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MICHAEL ANDREW FISCHBACH · 2019 to 2026
$17.0M
Research Support Core D: Clinical and Behavioral ServicesP30DA054557 · NIDA · CASE WESTERN RESERVE UNIVERSITY · PI LEVINE, ALAN DAVID · 2021 to 2025
$16.2M
Repairing the intestinal epithelium from the dual action of HIV and drug useDP1DA037997 · NIDA · CASE WESTERN RESERVE UNIVERSITY · PI LEVINE, ALAN DAVID · 2015 to 2019
$4.1M
Immunology Training Program-PredoctoralT32AI089474 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI COBB, BRIAN A · 2010 to 2025
$3.4M
Training Program in HIV CureT32AI127201 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI LEVINE, ALAN DAVID · 2016 to 2020
$919k
NHLBI NIH HHS P01 HL147823NIAID NIH HHS P30 AI036219NIAID NIH HHS T32 AI089474NIAID NIH HHS T32 AI127201NIDA NIH HHS DP1 DA037997NIDA NIH HHS P30 DA054557NIGMS NIH HHS T32 GM007250
6 · The paper itself

Abstract

Over the past three decades the United States has experienced a devastating opioid epidemic. One of the many debilitating side effects of chronic opioid use is opioid-induced bowel dysfunction. We investigated the impact of methadone maintenance treatment (MMT) on the gut microbiome, the gut bacterial metabolite profile, and intestinal barrier integrity. An imbalance in key bacterial communities required for production of short-chain fatty acids (SCFAs), mucus degradation, and maintenance of barrier integrity was identified. Consistent with dysbiosis, levels of fecal SCFAs were reduced in MMT. We demonstrated that metabolites synthesized by

Indexed as

AdultAnalgesics, OpioidAnimalsDysbiosisFemaleGastrointestinal MicrobiomeHealthy VolunteersHumansMaleMethadoneMiddle AgedOpioid-Related DisordersUnited StatesAnalgesics, OpioidMethadoneAkkermansia muciniphilaIntestinal permeabilitymetabolomicsmethadoneshort-chain fatty acidstight junctions

Identifiers

PMID34313547
PMCPMC8317955
OpenAlexW3184611696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.